Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Targeting virulence: a new paradigm for antimicrobial therapy

Nature Chemical Biology volume 3, pages 541–548 (2007)Cite this article

Abstract

Clinically significant antibiotic resistance has evolved against virtually every antibiotic deployed. Yet the development of new classes of antibiotics has lagged far behind our growing need for such drugs. Rather than focusing on therapeutics that target in vitro viability, much like conventional antibiotics, an alternative approach is to target functions essential for infection, such as virulence factors required to cause host damage and disease. This approach has several potential advantages including expanding the repertoire of bacterial targets, preserving the host endogenous microbiome, and exerting less selective pressure, which may result in decreased resistance. We review new approaches to targeting virulence, discuss their advantages and disadvantages, and propose that in addition to targeting virulence, new antimicrobial development strategies should be expanded to include targeting bacterial gene functions that are essential for in vivo viability. We highlight both new advances in identifying these functions and prospects for antimicrobial discovery targeting this unexploited area.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: Timeline of antibiotic deployment and the evolution of antibiotic resistance.
Figure 2: Traditional targets of antibacterial compounds.
Figure 3: Bacterial protein functions that can be targeted to inhibit virulence and examples of virulence inhibitors.

References

  1. Palumbi, S.R. Humans as the world's greatest evolutionary force. Science 293, 1786–1790 (2001).

    Article  PubMed  CAS  Google Scholar 

  2. Young, J.A. & Collier, R.J. Anthrax toxin: receptor-binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76, 243–265 (2007).

    Article  PubMed  CAS  Google Scholar 

  3. Boyden, E.D. & Dietrich, W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38, 240–244 (2006).

    Article  PubMed  CAS  Google Scholar 

  4. Duesbery, N.S. et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280, 734–737 (1998).

    Article  PubMed  CAS  Google Scholar 

  5. Vitale, G. et al. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248, 706–711 (1998).

    Article  PubMed  CAS  Google Scholar 

  6. Panchal, R.G. et al. Chemical genetic screening identifies critical pathways in anthrax lethal toxin-induced pathogenesis. Chem. Biol. 14, 245–255 (2007).

    Article  PubMed  CAS  Google Scholar 

  7. During, R.L. et al. Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation. EMBO J. 26, 2240–2250 (2007).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  8. Rainey, G.J. & Young, J.A. Antitoxins: novel strategies to target agents of bioterrorism. Nat. Rev. Microbiol. 2, 721–726 (2004).

    Article  PubMed  Google Scholar 

  9. Shoop, W.L. et al. Anthrax lethal factor inhibition. Proc. Natl. Acad. Sci. USA 102, 7958–7963 (2005).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Turk, B.E. et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11, 60–66 (2004).

    Article  PubMed  CAS  Google Scholar 

  11. Krantz, B.A. et al. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 309, 777–781 (2005).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Artenstein, A.W. et al. Chloroquine enhances survival in Bacillus anthracis intoxication. J. Infect. Dis. 190, 1655–1660 (2004).

    Article  PubMed  CAS  Google Scholar 

  13. Sanchez, A.M. et al. Amiodarone and bepridil inhibit anthrax toxin entry into host cells. Antimicrob. Agents Chemother 51, 2403–2411 (2007).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Moayeri, M., Wiggins, J.F., Lindeman, R.E. & Leppla, S.H. Cisplatin inhibition of anthrax lethal toxin. Antimicrob. Agents Chemother. 50, 2658–2665 (2006).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Ma, T. et al. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J. Clin. Invest. 110, 1651–1658 (2002).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  16. King, C.Y. & Barriere, S.L. Analysis of the in vitro interaction between vancomycin and cholestyramine. Antimicrob. Agents Chemother. 19, 326–327 (1981).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Galan, J.E. & Wolf-Watz, H. Protein delivery into eukaryotic cells by type III secretion machines. Nature 444, 567–573 (2006).

    Article  PubMed  CAS  Google Scholar 

  18. Kauppi, A.M., Nordfelth, R., Uvell, H., Wolf-Watz, H. & Elofsson, M. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem. Biol. 10, 241–249 (2003).

    Article  PubMed  CAS  Google Scholar 

  19. Nordfelth, R., Kauppi, A.M., Norberg, H.A., Wolf-Watz, H. & Elofsson, M. Small-molecule inhibitors specifically targeting type III secretion. Infect. Immun. 73, 3104–3114 (2005).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Muschiol, S. et al. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc. Natl. Acad. Sci. USA 103, 14566–14571 (2006).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Bailey, L. et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 581, 587–595 (2007).

    Article  PubMed  CAS  Google Scholar 

  22. Hudson, D.L. et al. Inhibition of type III secretion in Salmonella enterica serovar Typhimurium by small-molecule inhibitors. Antimicrob. Agents Chemother 51, 2631–2635 (2007).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Stevens, D.L., Gibbons, A.E., Bergstrom, R. & Winn, V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J. Infect. Dis. 158, 23–28 (1988).

    Article  PubMed  CAS  Google Scholar 

  24. Miller, M.B. & Bassler, B.L. Quorum sensing in bacteria. Annu. Rev. Microbiol. 55, 165–199 (2001).

    Article  PubMed  CAS  Google Scholar 

  25. Parsek, M.R., Val, D.L., Hanzelka, B.L., Cronan, J.E. Jr. & Greenberg, E.P. Acyl homoserine-lactone quorum-sensing signal generation. Proc. Natl. Acad. Sci. USA 96, 4360–4365 (1999).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  26. Dong, Y.H., Xu, J.L., Li, X.Z. & Zhang, L.H. AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of Erwinia carotovora. Proc. Natl. Acad. Sci. USA 97, 3526–3531 (2000).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Dong, Y.H. et al. Quenching quorum-sensing-dependent bacterial infection by an N-acyl homoserine lactonase. Nature 411, 813–817 (2001).

    Article  PubMed  CAS  Google Scholar 

  28. Yang, F. et al. Quorum quenching enzyme activity is widely conserved in the sera of mammalian species. FEBS Lett. 579, 3713–3717 (2005).

    Article  PubMed  CAS  Google Scholar 

  29. Draganov, D.I. et al. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46, 1239–1247 (2005).

    Article  PubMed  CAS  Google Scholar 

  30. Muh, U. et al. Novel Pseudomonas aeruginosa quorum-sensing inhibitors identified in an ultra-high-throughput screen. Antimicrob. Agents Chemother. 50, 3674–3679 (2006).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  31. Geske, G.D., Wezeman, R.J., Siegel, A.P. & Blackwell, H.E. Small molecule inhibitors of bacterial quorum sensing and biofilm formation. J. Am. Chem. Soc. 127, 12762–12763 (2005).

    Article  PubMed  CAS  Google Scholar 

  32. Smith, K.M., Bu, Y. & Suga, H. Induction and inhibition of Pseudomonas aeruginosa quorum sensing by synthtic autoinducer analogs. Chem. Biol. 10, 81–89 (2003).

    Article  PubMed  CAS  Google Scholar 

  33. Givskov, M. et al. Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. J. Bacteriol. 178, 6618–6622 (1996).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Manefield, M. et al. Halogenated furanones inhibit quorum sensing through accelerated LuxR turnover. Microbiology 148, 1119–1127 (2002).

    Article  PubMed  CAS  Google Scholar 

  35. Manefield, M., Welch, M., Givskov, M., Salmond, G.P. & Kjelleberg, S. Halogenated furanones from the red alga, Delisea pulchra, inhibit carbapenem antibiotic synthesis and exoenzyme virulence factor production in the phytopathogen Erwinia carotovora. FEMS Microbiol. Lett. 205, 131–138 (2001).

    Article  PubMed  CAS  Google Scholar 

  36. Hentzer, M. et al. Inhibition of quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated furanone compound. Microbiology 148, 87–102 (2002).

    Article  PubMed  CAS  Google Scholar 

  37. Hentzer, M. et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22, 3803–3815 (2003).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Wu, H. et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53, 1054–1061 (2004).

    Article  PubMed  CAS  Google Scholar 

  39. Yates, E.A. et al. N-acylhomoserine lactones undergo lactonolysis in a pH-, temperature-, and acyl chain length-dependent manner during growth of Yersinia pseudotuberculosis and Pseudomonas aeruginosa. Infect. Immun. 70, 5635–5646 (2002).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Muh, U. et al. A structurally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. Proc. Natl. Acad. Sci. USA 103, 16948–16952 (2006).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Lyon, G.J., Wright, J.S., Christopoulos, A., Novick, R.P. & Muir, T.W. Reversible and specific extracellular antagonism of receptor-histidine kinase signaling. J. Biol. Chem. 277, 6247–6253 (2002).

    Article  PubMed  CAS  Google Scholar 

  42. Mayville, P. et al. Structure-activity analysis of synthetic autoinducing thiolactone peptides from Staphylococcus aureus responsible for virulence. Proc. Natl. Acad. Sci. USA 96, 1218–1223 (1999).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  43. Wright, J.S. III, Jin, R. & Novick, R.P. Transient interference with staphylococcal quorum sensing blocks abscess formation. Proc. Natl. Acad. Sci. USA 102, 1691–1696 (2005).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  44. Hung, D.T., Shakhnovich, E.A., Pierson, E. & Mekalanos, J.J. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670–674 (2005).

    Article  PubMed  CAS  Google Scholar 

  45. Gauthier, A. et al. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob. Agents Chemother. 49, 4101–4109 (2005).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  46. Sauer, F.G. et al. Chaperone-assisted pilus assembly and bacterial attachment. Curr. Opin. Struct. Biol. 10, 548–556 (2000).

    Article  PubMed  CAS  Google Scholar 

  47. Svensson, A. et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. ChemBioChem 2, 915–918 (2001).

    Article  PubMed  CAS  Google Scholar 

  48. Pinkner, J.S. et al. Rationally designed small compounds inhibit pilus biogenesis in uropathogenic bacteria. Proc. Natl. Acad. Sci. USA 103, 17897–17902 (2006).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Lee, Y.M., Almqvist, F. & Hultgren, S.J. Targeting virulence for antimicrobial chemotherapy. Curr. Opin. Pharmacol. 3, 513–519 (2003).

    Article  PubMed  CAS  Google Scholar 

  50. Sassetti, C.M. & Rubin, E.J. Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. USA 100, 12989–12994 (2003).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  51. MacRae, C.A. & Peterson, R.T. Zebrafish-based small molecule discovery. Chem. Biol. 10, 901–908 (2003).

    Article  PubMed  CAS  Google Scholar 

  52. Peterson, R.T. et al. Chemical suppression of a genetic mutation in a zebrafish model of aortic coarctation. Nat. Biotechnol. 22, 595–599 (2004).

    Article  PubMed  CAS  Google Scholar 

  53. Stern, H.M. et al. Small molecules that delay S phase suppress a zebrafish bmyb mutant. Nat. Chem. Biol. 1, 366–370 (2005).

    Article  PubMed  CAS  Google Scholar 

  54. Davis, J.M. et al. Real-time visualization of Mycobacterium-macrophage interactions leading to initiation of granuloma formation in zebrafish embryos. Immunity 17, 693–702 (2002).

    Article  PubMed  CAS  Google Scholar 

  55. Neely, M.N., Pfeifer, J.D. & Caparon, M. Streptococcus-zebrafish model of bacterial pathogenesis. Infect. Immun. 70, 3904–3914 (2002).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. van der Sar, A.M. et al. Zebrafish embryos as a model host for the real time analysis of Salmonella typhimurium infections. Cell. Microbiol. 5, 601–611 (2003).

    Article  PubMed  CAS  Google Scholar 

  57. Mukhopadhyay, A. & Peterson, R.T. Fishing for new antimicrobials. Curr. Opin. Chem. Biol. 10, 327–333 (2006).

    Article  PubMed  CAS  Google Scholar 

  58. Moy, T.I. et al. Identification of novel antimicrobials using a live-animal infection model. Proc. Natl. Acad. Sci. USA 103, 10414–10419 (2006).

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  59. Payne, D.J., Gwynn, M.N., Holmes, D.J. & Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29–40 (2007).

    Article  PubMed  CAS  Google Scholar 

  60. Lipinski, C.A., Lombardo, F., Dominy, B.W. & Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3–26 (2001).

    Article  PubMed  CAS  Google Scholar 

  61. Schreiber, S.L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964–1969 (2000).

    Article  CAS  PubMed  Google Scholar 

  62. Sarac, M.S., Peinado, J.R., Leppla, S.H. & Lindberg, I. Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo. Infect. Immun. 72, 602–605 (2004).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

We thank E.J. Rubin, J.E. Gomez and S.A. Stanley for helpful discussions and critical reading of this manuscript and J.S.W. Lee for assistance in preparing figures.

Author information

Authors and Affiliations

  1. Department of Molecular Biology and Center for Computational and Integrative Biology, USA; Department of Microbiology and Molecular Genetics, Massachusetts General Hospital, 185 Cambridge St., Boston, Massachusetts 02114, Harvard Medical School, 200 Longwood Ave., Boston, Massachusetts 02115, USA; and the Broad Institute of MIT and Harvard, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA.,

    Anne E Clatworthy, Emily Pierson & Deborah T Hung

  2. Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Ave., Boston, Massachusetts 02115, USA,

    Anne E Clatworthy, Emily Pierson & Deborah T Hung

Authors
  1. Anne E Clatworthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emily Pierson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Deborah T Hung
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Deborah T Hung.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Clatworthy, A., Pierson, E. & Hung, D. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 3, 541–548 (2007). https://doi.org/10.1038/nchembio.2007.24

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio.2007.24

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing